Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.83 |
| ▸ | CES2 | O00748 | 1/20 | 0.83 |
| ▸ | USP19 | O94966 | 3/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426010 | 0.92 | FAAH (0.98) | FAAHCES2USP19HSP90AA1GPR119 | |
| SCHEMBL29683887 | 0.91 | FAAH (1.00) | FAAHCES2USP19HSP90AA1TRPV1 | |
| SCHEMBL427970 | 0.91 | FAAH (1.00) | FAAHCES2USP19HSP90AA1TRPV1 | |
| SCHEMBL426101 | 0.89 | FAAH (0.81) | FAAHCES2USP19HSP90AA1AOC3 | |
| SCHEMBL427995 | 0.86 | FAAH (0.60) | FAAHCES2USP19HSP90AA1AOC3 | |
| SCHEMBL426169 | 0.85 | FAAH (0.75) | FAAHCES2USP19HSP90AA1 | |
| SCHEMBL426088 | 0.83 | FAAH (0.72) | FAAHCES2 | |
| SCHEMBL427890 | 0.81 | FAAH (0.55) | FAAHCES2USP19HSP90AA1AOC3 | |
| SCHEMBL7901851 | 0.79 | FAAH (0.79) | FAAHCES2USP19TRPV1TRPA1 | |
| SCHEMBL425904 | 0.79 | FAAH (0.66) | FAAHCES2HSP90AA1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885USP19 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.